HOME >> BIOLOGY >> NEWS
National Eye Institute funds search for genetic key to corneal disease

HOUSTON (Nov. 5, 2004) A new federal grant focusing on painful inherited visual disorders that scar the cornea will allow researchers to narrow the genetic cause of one type of corneal dystrophy and to offer improved diagnosis of this family of diseases.

The $1.1 million, three-year award by the National Eye Institute funds follow-up research on Thiel-Behnke Corneal Dystrophy by principal investigators Richard W.Yee, M.D., clinical professor, and Xinping Zhao, Ph.D., assistant professor, both of the Department of Ophthalmology and Visual Science at The University of Texas Medical School at Houston.

"Thiel-Behnke causes spots of varying shape they can look sort of like a fingerprint or be a dense patch blocking out light on the front layer of cells in the cornea," Yee said. "Onset can occur as early as infancy, as late as adolescence, and is accompanied by a sharp, stabbing pain. The spots can be visually debilitating." The cornea is the curved, transparent layer at the very front of the eye.

Yee, Zhao, and UT School of Public Health Human Genetics Center colleagues Stephen Daiger, Ph.D., and Lori Sullivan, Ph.D., previously narrowed the genetic cause of Thiel-Behnke to a short portion of DNA on chromosome 10. The NEI grant will fund an intensive effort to pinpoint the culprit variation among possible genes on that strip of the chromosome, clarifying the molecular cause of the disease.

Once treatable only by corneal transplantation, Thiel-Behnke is now treated by laser surgery but can still result in loss of vision, Yee said.

In addition to understanding the origins of Thiel-Behnke, Yee anticipates that the grant will allow his team to help diagnose other varieties of corneal dystrophy.

"There are many types of dystrophy and it's difficult to discern them just by looking at them," Yee said. "Physicians will be able to send us blood samples of patients, which we can screen for known mutations using genetic markers -- not just for
'"/>

Contact: Scott Merville
scott.merville@uth.tmc.edu
713-500-3042
University of Texas Health Science Center at Houston
5-Nov-2004


Page: 1 2

Related biology news :

1. Story tips from the US Department of Energys Oak Ridge National Laboratory, August 2007
2. National Ecological Observatory Network featured at ESA/SER Joint International Conference
3. Smithsonians National Zoo researchers use electronic eggs to help save threatened species
4. Bumblebees make bee line for gardens, National Bumblebee Nest Survey finds
5. Elsevier partners with National Natural Science Foundation of China
6. President Bush announces 2005 and 2006 Laureates of National Medals of Science and Technology
7. Fedoroff, of Penn State, to receive National Medal of Science
8. Story tips from the Department of Energys Oak Ridge National Laboratory
9. Los Alamos National Laboratory making progress in Groundwater Protection Program
10. Candidate research sites selected for the National Ecological Observatory Network
11. Computer science professor awarded $400,000 from National Science Foundation

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: National Eye Institute funds search for genetic key corneal disease

(Date:2/13/2015)... , Feb. 13, 2015 ACT ... company that aims to transform cancer genomic information ... that the company has raised US$ 8 million in ... Based in Taipei, Taiwan , ... ACTDrug™, ACTOnco™. With the aim to implement next ...
(Date:2/9/2015)... RICHARDSON, Texas , Feb. 9, 2015  Lintec ... novel fabrication methods for carbon nanotube (CNT) macrostructures, including ... Texas at Dallas (UTD). Leveraging the vast ... Tokyo, Japan , Lintec of America ... Richardson, TX , focusing on scaling ...
(Date:2/5/2015)... 2015   Marvin Test Solutions , ... test solutions for military, aerospace, and manufacturing ... TS-323 GENASYS Test Platform to ... is a high-performance PXI-based system designed to ... require performance functional testing. GENASYS features a ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
(Date:2/28/2015)... 2015 Increasing its efforts to resolve the ... first three episodes of The GMO TRUTH podcast on both ... as it continues its mission to discover the truth and ... phase, to “uncover the truth about the GMOs in our ... GMO Truth Podcast is an expansion of the documentary/investigative film-making ...
(Date:2/27/2015)... Calif. , Feb. 27, 2015  Pharmacyclics, ... that longer-term toxicology studies for its newly developed ... or RA, have been completed. The results of ... U.S. Food and Drug Administration. The feedback received ... of the ongoing first-in-human study. Additional preclinical work ...
(Date:2/27/2015)... Halifax, Nova Scotia (PRWEB) February 27, 2015 ... clinical stage vaccine and immunotherapy company, today announced ... approved its application for Fast Track designation and ... DPX-Ebola vaccines, in conjunction with the mutual co-development ... had previously obtained Fast Track designation for the ...
(Date:2/27/2015)... , Feb. 27, 2015  Pfenex Inc. (NYSE ... development of biosimilar therapeutics, today announced that it will ... Marriott Marquis on March 2 nd at 3pm ... on a panel discussing the current state of the ... Biosimilars . For more information on ...
Breaking Biology Technology:The Walk a Mile Project Launches “GMO Truth” Podcast 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3
Cached News: